Literature DB >> 33811833

Malignant Syphilis: A Systematic Review of the Case Reports Published in 2014-2018.

O Wibisono1, I Idrus2, K Djawad3.   

Abstract

Malignant syphilis (MS) is a rare manifestation of secondary syphilis which mainly occurs in immunocompromised individuals such as those coinfected with human immunodeficiency virus (HIV). However, recent reports have described MS in immunocompetent individuals. To describe the characteristics of individuals with MS and associated risk factors, a review of case reports published from 2014 to 2018 was conducted. Out of 45 published case reports, 33 cases (73%) occurred in HIV-positive individuals with majority having CD4 counts < 500 cells/mm3. Of the 12 cases (27%) in HIV-negative individuals, half had comorbidities such as diabetes mellitus, alcoholism, drug abuse, psoriasis, and hepatitis. The most frequent manifestation of MS was ulceronodular cutaneous lesions with central adherent crust, which affected the face, trunk, and limbs. Given the increasing number of MS regardless of the immune status, dermatologists and general practitioners should be vigilant to allow early diagnosis and treatment, hence reducing their morbidity.
Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  HIV infection; Immuno deficiency; Infección por VIH; Inmuno deficiencia; Malignant syphilis; Sífilis maligna; Treponema pallidum

Year:  2021        PMID: 33811833     DOI: 10.1016/j.ad.2021.02.011

Source DB:  PubMed          Journal:  Actas Dermosifiliogr (Engl Ed)        ISSN: 2173-5778


  2 in total

1.  Ulceronecrotic rash in an immunocompetent individual.

Authors:  Shae Margulies; Sagar P Patel; Kiran Motaparthi
Journal:  JAAD Case Rep       Date:  2022-07-05

2.  Malignant Syphilis in a Female Patient: A Case Report and Mini-Review.

Authors:  Julija Dimnik; Maja Benko; Violeta Hosta; Andreja Murnik Rauh; Andreja Pagon; Vesna Cvitković Špik; Saba Battelino; Domen Vozel
Journal:  Trop Med Infect Dis       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.